Android app on Google Play

Acadia Pharmaceuticals, (ACAD) Prices 8M Share Offering at $12.50/Sh

May 15, 2013 8:03 AM EDT Send to a Friend
Get Alerts ACAD Hot Sheet
Trade ACAD Now!
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $12.50 per share.

The gross proceeds from this offering to ACADIA are expected to be $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 1,200,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about May 20, 2013, subject to customary closing conditions. ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.

Jefferies LLC and Cowen and Company, LLC are acting as the joint book-running managers for the offering. JMP Securities LLC, Needham & Company, LLC, Ladenburg Thalmann & Co. Inc., Roth Capital Partners, LLC, and SunTrust Robinson Humphrey, Inc. are acting as co-managers for the offering.




You May Also Be Interested In


Related Categories

Equity Offerings

Related Entities

Jefferies & Co, Needham & Company, Roth Capital, JMP Securities, SunTrust Robinson Humphrey, Ladenburg Thalmann Financial Services, Cowen & Co

Add Your Comment